To the Editor: Biosimilars are medications that have no clinically meaningful differences in terms of safety, purity, and potency relative to a reference drug product that has already obtained approval from the Food and Drug Administration. 1 These drugs are often investigated by equivalence trials wherein the biosimilar is determined clinically to be neither inferior nor superior when compared with its originator. Because of the complex molecular nature of biosimilars, manufacturing identical replicas of corresponding originators is impossible. [2] [3] [4] Thus, it is crucial to decide upon the acceptable margin of error (MoE), which is defined as the maximum allowable difference in a standard treatment outcome measure between the biosimilar and originator. Therefore, it is critical to understand the MoE in studies on biosimilars to determine if potentially clinically important differences in efficacy were ruled out statistically by study design.
We conducted a systematic review using MEDLINE, Embase, Cochrane Central Register of Controlled Trials, LILACS, and ClinicalTrials.gov from inception through February 17, 2017. To obtain data from unpublished or unidentified studies, we searched clinicaltrialresults.org and contacted corresponding authors. Our inclusion criteria included patients $18 years of age with plaque psoriasis randomized to receive the biosimilar or originator with measured Psoriasis Area and Severity Index (PASI) endpoints at week 12 or later.
We abstracted the following data: study design, sample size, study power, confidence intervals, MoE, outcomes, and response rates. Four clinical trials that included 1746 adult patients qualified for inclusion; the MoEs in these reports ranged from 614% to 618% (Fig 1, Table I ). Five clinical trials were excluded because the information available was not sufficient, and industry sponsors declined to provide this information upon request.
These margins, which were decided upon by regulatory bodies, might be unacceptably wide (eg, imprecise) to some prescribing clinicians. For example, if the true PASI 75 response rates were 65% and 50% for the originator and biosimilar, respectively, this would be considered equivalent responses in a study with 615% MoE. One physician might consider these parameters sufficient and comfortably prescribe the biosimilar as a replacement for the originator; however, another clinician might require more conservative margins. Moreover, this quandary is compounded by factors that influence the MoE such as the study's sample size. For example, a trial powered at 0.80 with a 615% MoE would require, based on typical statistical specifications needed in clinical trials, 382 patients. However, the identical study with the same parameters yet mandating a 610% MoE would require an additional 476 patients (n ¼ 858). Other aspects of a study, such as the variability in the study population, expertise, and geographic location of the study sites, are critical to understand, yet are not understood by the average practitioner.
As biosimilar approvals accrue and their use increases, possibly delivering decreased healthcare costs and better patient access, practitioners require a deeper understanding of the design and conduct of clinical trials to better interpret the true likelihood of achieving the same clinical outcome regardless of drug choice. Prevalence of chronic hepatitis B and C in psoriasis patients: A cross-sectional study in a large US population
To the Editor: An association between psoriasis and hepatitis B and C is inconsistently reported in the literature. [1] [2] [3] Because both hepatitis B and C viruses have been hypothesized to exacerbate psoriasis and because biologic treatments for psoriasis may be contraindicated in patients infected with hepatitis viruses, exploring this possible relationship for each virus may lead to better management. 1 Consequently, this study aimed to determine the prevalence of hepatitis B and C in patients with psoriasis within a large, single-center, US patient population.
Under an Institutional Review Boardeapproved protocol, we utilized a large, urban, electronic medical record data repository, Northwestern Medicine Enterprise Data Warehouse (NMEDW) with data on more than 4 million individuals. 4 A very high percentage of the patients in the NMEDW data repository are from the Chicago metropolitan area. A very small minority of patients are from surrounding states and/or rural areas. All patients, regardless of billing status, are included. We searched the NMEDW for all patients aged 18 to 89 years who underwent hepatitis B and/or C serology screening between September 2010 and September 2016. We then divided this group into those with a diagnosis of psoriasis . Logistic regression analysis was performed to obtain odds ratios (ORs) with 95% confidence intervals (CIs) and corresponding P values.
A total of 114,855 patients underwent hepatitis B and/or C screening (Table I ). The frequency of hepatitis B and/or C is shown in Table II . There was no significant difference between the populations with and without psoriasis in terms of prevalence of hepatitis B (OR, 0.56; 95% CI, 0.34-1.03; P ¼ .064) or hepatitis C (OR, 0.8; 95% CI, 0.57-1.13; P ¼ .2).
Using a cross-sectional design to analyze a large, urban, single-center, midwestern US patient population, this study found no significant difference in prevalence for chronic hepatitis B or C in patients with psoriasis compared with in those without psoriasis. Limitations of this study include the cross-sectional design, the lack of adjustment for additional risk factors for hepatitis B and C, and the inability to assess prevalence of hepatitis B and/or C in patients with psoriasis who were not screened for hepatitis. Additionally, prevalence might have been affected by differences in demographics between psoriasis and control populations. Moreover, this study, although informed by data on a large number of patients, was conducted in a single, urban, multiethnic, academic-based medical center and is therefore not viewed as representative of the general population. Strengths of this study include its large 
